<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363075">
  <stage>Registered</stage>
  <submitdate>25/09/2012</submitdate>
  <approvaldate>25/09/2012</approvaldate>
  <actrnumber>ACTRN12612001032842</actrnumber>
  <trial_identification>
    <studytitle>Effectiveness of liquid special diet to induce gut healing when used as a sole nutrition for newly diagnosed children with Crohn's Disease.</studytitle>
    <scientifictitle>Exclusive enteral nutrition and mucosal healing in newly diagnosed children with Crohns disease : Comparison of clinical parameters, biomarkers, microbiome and genotype between responders and non-responders.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The diagnosis of Crohns disease willbe based on established clinical, endoscopic, histological and radiological criteria.  Children will be given either Nutrison (1Kcal/ml, Nutricia UK) through Nasogastric tube (NGT) or Resource (Nestle) orally after dietetic consultation for total duration of 8 weeks.Prescribed volume will base on estimated caloric requirement aiming to gradully upgrade target volume in 3 to 5 days. In those electing NG tube, insertion can be performed during General Anaesthetic for the diagnostic endoscopy. Children struggling with oral EEN can be offered different flavours or changes to NG route. Clear fluids, Jelly, boiled lollies were allowed empirically and concurrently to improve palatability. A comprehensive evaluation including clinical, standard laboratory, Colonoscopy (review gut lining) and MRE (bowel wall thickness) will be undertaken at diagnosis and after treatment. Faecal samples, additional blood and small tissue biopsies will be collected on both occasions.Other therapies like steroids and early introduction of Imuran before first relapse may be used due to patient preference or clinician discretion but patients will undergo similar assessments at initial visit and 8 weeks.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary end points of the study are to determine efficacy of EEN for inducing early clinical, biochemical, mucosal and transmural remission at 8 weeks. 

Measurement at diagnosis and 8 weeks:

PCDAI=  Clinical and Biochemistry including CRP
BMI Z=   Growth measurements
Mucosal healing= Endoscopic Scoring ( Colonoscopy)
Transmural Healing = MR Enterography</outcome>
      <timepoint>At Diagnosis and 8 weeks.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Relate early endoscopic response to subsequent clinical outcomes, specifically endoscopic confirmed relapse, hospitalisation, need to commence biological agent and surgical resection</outcome>
      <timepoint>12 and 24 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>After an initial expected enrolment of 20 children interim mechanistic analyses will be done to refine the outlined hypotheses. 
Additional 30 patients will be enrolled subsequently to identify the changes in mucosal cytokine T regulatory profiles, faecal and mucosal microbiota, genotypes of EEN responders versus EEN non responders and versus those electing for steroids to better understand mechanism of EEN induced remission , target dietary interventions and develop risk stratification of patients.

24 months

Faecal microbiome :  Pyrosequencing for microbiome
Mucosal biopsy for Cytokines, T reg &amp; microbiome:  ELISA , Microarray, Immunohistochemistry 
Blood T reg profile:  Flow cytometry</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>New Diagnosis of Paediatric Crohn's disease</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria included previous exposure to: steroids, conventional Immunomodulators, biological agents; and inability to tolerate oral or Nasogastric (NG) tube EEN for a minimum of 6 weeks.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>None</concealment>
    <sequence>None</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>8/03/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr.Zubin Grover</primarysponsorname>
    <primarysponsoraddress>QCMRI
RCH Foundation Building
Herston Road
Herston
4006
QLD
Brisbane</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>ANZ Trustees</fundingname>
      <fundingaddress>ANZ Trustees Limited 
Australia and New Zealand Banking Group Limited 
Postal Address: GPO Box 389 Melbourne Vic 3001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Queensland Childrens Medical Research Institute</fundingname>
      <fundingaddress>RCH Foundation Building
Herston Road
Herston
4006
Brisbane
QLD</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Queensland Children Medical Research Institute</sponsorname>
      <sponsoraddress>QCMRI
RCH Foundation Building
Herston Road
Herston 4006
Brisbane
QLD</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This proposal will confirm short term benefits of EEN on mucosal recovery and, on follow up, the favorable impact on clinical course. It will demonstrate utility or otherwise of phenotypic, genetic, biomarkers and faecal calprotectin to predict response. Mucosal and microbiome characteristics of patients with mucosal recovery will be compared with non responders to better understand mechanisms of efficacy of EEN with expectation of better targeted, safer, better tolerated, non-pharmacological therapies to induce mucosal healing and improve outcomes for children with Crohns disease.</summary>
    <trialwebsite>NA</trialwebsite>
    <publication>Oral Presentation Digestive Disease Week ,San Diego May 2012</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queensland Childrens Health Servuce District (RCH) Ethics Committe</ethicname>
      <ethicaddress>Level 3 Foundation Building
RCH Herston
Herston Road
4006
Brisbane
QLD</ethicaddress>
      <ethicapprovaldate>8/03/2010</ethicapprovaldate>
      <hrec>HREC/09/QRCH/128</hrec>
      <ethicsubmitdate>21/11/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr.Zubin Grover</name>
      <address>QCMRI
Herston Road
Herston
4006
Brisbane
QLD</address>
      <phone>+61736368015</phone>
      <fax>+61736363472</fax>
      <email>z.grover@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr.Zubin Grover</name>
      <address>QCMRI
RCH Foundation building
Herston Road
Herston
4006
Brisbane
QLD</address>
      <phone>+61-736368015</phone>
      <fax>+61736363472</fax>
      <email>z.grover@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr.Zubin Grover</name>
      <address>QCMRI
Herston Road
Herston
4006</address>
      <phone>+61736368015</phone>
      <fax>+61736363472</fax>
      <email>z.grover@uq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>